Differentiation of prostatitis and prostate cancer by using diffusion-weighted MR imaging and MR-guided biopsy at 3 T

Radiology

Volumn 267, Issue 1, 2013, Pages 164-172

  Nagel, Klaas N A ^a   Schouten, Martijn G ^b   Hambrock, Thomas ^b   Litjens, Geert J S ^b   Hoeks, Caroline M A ^b   Ten Haken, Bennie ^a   Barentsz, Jelle O ^b   Fütterer, Jurgen J ^b  

^a UNIVERSITY OF TWENTE   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; COMPUTER ASSISTED DIAGNOSIS; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE GUIDED BIOPSY; LABORATORY DEVICE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATITIS; RETROSPECTIVE STUDY; THICKNESS; TISSUE TYPING;

AGED; BIOPSY; DIAGNOSIS, DIFFERENTIAL; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LINEAR MODELS; MAGNETIC RESONANCE IMAGING, INTERVENTIONAL; MALE; PROSTATIC NEOPLASMS; PROSTATITIS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 84875452567     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12111683     Document Type: Article

References (46)

1. Hochreiter WW. The issue of prostate cancer evaluation in men with elevated prostate- specific antigen and chronic prostatitis. Andrologia 2008;40(2):130-133.
2. Battikhi MN, Hussein I. Age-specific reference ranges for prostate specific antigentotal and free in patients with prostatitis symptoms and patients at risk. Int Urol Nephrol 2006;38(3-4):559-564.
3. Ozden C, Ozdal OL, Guzel O, Han O, Seckin S, Memis A. The correlation between serum prostate specific antigen levels and asymptomatic inflammatory prostatitis. Int Urol Nephrol 2007;39(3):859-863.
4. Collins MM, Stafford RS, O'Leary MP, Barry MJ. How common is prostatitis? A national survey of physician visits. J Urol 1998; 159(4):1224-1228.
5. Yu KK, Hricak H. Imaging prostate cancer. Radiol Clin North Am 2000;38(1): 59-85, viii.
6. Fütterer JJ. MR imaging in local staging of prostate cancer. Eur J Radiol 2007; 63(3):328-334.
7. Engelbrecht MR, Jager GJ, Laheij RJ, Verbeek AL, van Lier HJ, Barentsz JO. Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol 2002;12(9):2294-2302.
8. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with threedimensional proton MR spectroscopic imaging - clinicopathologic study. Radiology 1999;213(2):473-480.
9. Quint LE, Van Erp JS, Bland PH, et al. Prostate cancer: correlation of MR images with tissue optical density at pathologic examination. Radiology 1991;179(3):837-842.
10. Lovett K, Rifkin MD, McCue PA, Choi H. MR imaging characteristics of noncancerous lesions of the prostate. J Magn Reson Imaging 1992;2(1):35-39.
11. Schiebler ML, Tomaszewski JE, Bezzi M, et al. Prostatic carcinoma and benign prostatic hyperplasia: correlation of high-resolution MR and histopathologic findings. Radiology 1989;172(1):131-137.
12. Kim CK, Park BK, Kim B. Localization of prostate cancer using 3T MRI: comparison of T2-weighted and dynamic contrastenhanced imaging. J Comput Assist Tomogr 2006;30(1):7-11.
13. Engelbrecht MR, Huisman HJ, Laheij RJ, et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 2003;229(1): 248-254.
14. Yakar D, Hambrock T, Huisman H, et al. Feasibility of 3T dynamic contrast-enhanced magnetic resonance-guided biopsy in localizing local recurrence of prostate cancer after external beam radiation therapy. Invest Radiol 2010;45(3):121-125.
15. Heijmink SW, Scheenen TW, Fütterer JJ, et al. Prostate and lymph node proton magnetic resonance (MR) spectroscopic imaging with external array coils at 3 T to detect recurrent prostate cancer after radiation therapy. Invest Radiol 2007;42(6):420-427.
16. Wang L, Hricak H, Kattan MW, Chen HN, Scardino PT, Kuroiwa K. Prediction of organ- confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 2006;238(2):597-603.
17. Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Threedimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 1996;198(3):795-805.
18. Gibbs P, Tozer DJ, Liney GP, Turnbull LW. Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate. Magn Reson Med 2001;46(6):1054-1058.
19. Issa B. In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging. J Magn Reson Imaging 2002;16(2):196-200.
20. Chan I, Wells W 3rd, Mulkern RV, et al. Detection of prostate cancer by integration of line-scan diffusion, T2-mapping and T2- weighted magnetic resonance imaging; a multichannel statistical classifier. Med Phys 2003;30(9):2390-2398.
21. Miao H, Fukatsu H, Ishigaki T. Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging. Eur J Radiol 2007;61(2):297-302.
22. Pickles MD, Gibbs P, Sreenivas M, Turnbull LW. Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0T. J Magn Reson Imaging 2006;23(2): 130-134.
23. Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S. Prostate cancer screening: the clinical value of diffusionweighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007;25(1): 146-152.
24. Shimofusa R, Fujimoto H, Akamata H, et al. Diffusion-weighted imaging of prostate can cer. J Comput Assist Tomogr 2005;29(2): 149-153.
25. Hosseinzadeh K, Schwarz SD. Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J Magn Reson Imaging 2004;20(4):654-661.
26. Sato C, Naganawa S, Nakamura T, et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging 2005;21(3):258-262.
27. Tamada T, Sone T, Jo Y, et al. Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging 2008;28(3): 720-726.
28. Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001;166(1):86-91; discussion 91-92.
29. Salomon L, Colombel M, Patard JJ, et al. Value of ultrasound-guided systematic sextant biopsies in prostate tumor mapping. Eur Urol 1999;35(4):289-293.
30. Amsellem-Ouazana D, Younes P, Conquy S, et al. Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. Eur Urol 2005;47(5):582-586.
31. Yoshimitsu K, Kiyoshima K, Irie H, et al. Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: correlation with stepwise histopathology. J Magn Reson Imaging 2008;27(1): 132-139.
32. Kim CK, Park BK, Lee HM, Kwon GY. Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results. Invest Radiol 2007;42(12): 842-847.
33. Van As N, Charles-Edwards E, Jackson A, et al. Correlation of diffusion-weighted MRI with whole mount radical prostatectomy specimens. Br J Radiol 2008;81(966): 456-462.
34. Hambrock T, Somford DM, Huisman HJ, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 2011;259(2):453-461.
35. Drew B, Jones EC, Reinsberg S, Yung AC, Goldenberg SL, Kozlowski P. Device for sectioning prostatectomy specimens to facilitate comparison between histology and in vivo MRI. J Magn Reson Imaging 2010; 32(4):992-996.
36. Yakar D, Hambrock T, Hoeks C, Barentsz JO, Fütterer JJ. Magnetic resonance-guided biopsy of the prostate: feasibility, technique, and clinical applications. Top Magn Reson Imaging 2008;19(6):291-295.
37. Vos PC, Hambrock T, Hulsbergen-van de Kaa CA, Fütterer JJ, Barentsz JO, Huisman HJ. Computerized analysis of prostate lesions in the peripheral zone using dynamic contrast enhanced MRI. Med Phys 2008;35(3):888-899.
38. Hambrock T, Fütterer JJ, Huisman HJ, et al. Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility. Invest Radiol 2008; 43(10):686-694.
39. Akin O, Sala E, Moskowitz CS, et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology 2006;239(3):784- 792.
40. Fütterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006;241(2):449-458.
41. Anastasiadis AG, Lichy MP, Nagele U, et al. MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol 2006;50(4):738-748; discussion 748-749.
42. Beyersdorff D, Winkel A, Hamm B, Lenk S, Loening SA, Taupitz M. MR imagingguided prostate biopsy with a closed MR unit at 1.5 T: initial results. Radiology 2005; 234(2):576-581.
43. Hambrock T, Somford DM, Hoeks C, et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 2010;183(2):520-527.
44. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005;29(9): 1228-1242.
45. Roethke M, Anastasiadis AG, Lichy M, et al. MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol 2012;30(2):213- 218.
46. Ukimura O, Hirahara N, Fujihara A, et al. Technique for a hybrid system of realtime transrectal ultrasound with preoperative magnetic resonance imaging in the guidance of targeted prostate biopsy. Int J Urol 2010;17(10):890-893.